There is a definite place of chemotherapy, radiotherapy, surgical resection as well as supportive care in the treatment of non small cell lung cancer. The author summarizes the therapeutic options of non small cell lung cancer according to literature results and also his own experiences. In the recent years advances in the chemotherapy of non small cell lung cancer could be observed. Large international studies are ongoing to evaluate the effectiveness of platinum based adjuvant cytostatic treatment in patients with early stage non small cell lung cancer. Patients with ipsilateral mediastinal lymph node involvement (N2) can be treated with chemotherapy as well as with surgical resection and postoperative irradiation. In the locally advanced stage the combination of chemotherapy and radiotherapy should be applied. The use of new cytostatic drugs (taxanes, gemcitabine, vinorelbine, topoisomerase inhibitors) combined with platinum derivates can improve the therapeutic response rate and also expected survival. The combination of new drugs with each other or the use of three drugs are under investigation. However, it is important to emphasize the importance of optimum supportive care in all stages of the disease in order to keep the quality of life of the patients at the highest possible level.
|Translated title of the contribution||Therapeutic options of non small cell lung cancer - Present aspects of chemotherapy|
|Number of pages||6|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Nov 3 1999|
ASJC Scopus subject areas